Lymphatic vascular effects of Ang1 are inhibited by systemic delivery of adenoviruses encoding the VEGFR-3-Ig fusion protein. (A-B) Anti-VEGFR-3-stained lymphatic vessel sprouts 10 days after transduction of AdAng1 (arrowheads in A) or AdAng1 plus systemic (s) AdVEGFR-3-Ig (B). (C-D) Confocal imaging of LYVE-1-stained lymphatic capillary ends 14 days after AdAng1 administration. Filopodia formed in response to AdAng1 treatment are indicated with arrows in panel C, while no filopodia can be seen in the AdAng1 plus AdVEGFR-3-Ig-treated ears (D). (C inset) A lymphatic vessel after AdLacZ transduction. Scale bars: 100 μm.